ZA200507158B - Treatment of incontinence with 5HTC2 agonists - Google Patents

Treatment of incontinence with 5HTC2 agonists Download PDF

Info

Publication number: ZA200507158B
Authority: ZA; South Africa
Prior art keywords: compound; alkyl; tetrahydro; hydrogen; alkoxy
Prior art date: 2003-04-25

Application number

ZA200507158A

Other languages

English (en)

Inventor

Mcmurray Gordon

Miner Wesley Dennis

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-25

Filing date

2005-09-06

Publication date

2006-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33397006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200507158(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-06 Application filed by Pfizer filed Critical Pfizer

2006-11-29 Publication of ZA200507158B publication Critical patent/ZA200507158B/en

Links

239000000556 agonist Substances 0.000 title claims description 40
206010021639 Incontinence Diseases 0.000 title claims description 39
238000011282 treatment Methods 0.000 title claims description 31
150000001875 compounds Chemical class 0.000 claims description 159
239000001257 hydrogen Substances 0.000 claims description 107
229910052739 hydrogen Inorganic materials 0.000 claims description 107
102000006902 5-HT2C Serotonin Receptor Human genes 0.000 claims description 78
125000000217 alkyl group Chemical group 0.000 claims description 69
108010072553 5-HT2C Serotonin Receptor Proteins 0.000 claims description 68
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 63
-1 oxy, thio, amino Chemical group 0.000 claims description 57
229910052736 halogen Inorganic materials 0.000 claims description 54
230000000694 effects Effects 0.000 claims description 44
239000000018 receptor agonist Substances 0.000 claims description 40
229940044601 receptor agonist Drugs 0.000 claims description 40
150000002367 halogens Chemical class 0.000 claims description 37
150000002431 hydrogen Chemical group 0.000 claims description 37
238000000034 method Methods 0.000 claims description 37
125000003545 alkoxy group Chemical group 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 31
229920006395 saturated elastomer Polymers 0.000 claims description 28
239000000203 mixture Substances 0.000 claims description 25
230000004044 response Effects 0.000 claims description 24
125000003282 alkyl amino group Chemical group 0.000 claims description 23
238000012360 testing method Methods 0.000 claims description 23
229910052799 carbon Inorganic materials 0.000 claims description 22
125000005843 halogen group Chemical group 0.000 claims description 21
229910052791 calcium Inorganic materials 0.000 claims description 19
238000003556 assay Methods 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 18
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 16
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 16
238000009472 formulation Methods 0.000 claims description 14
125000004093 cyano group Chemical group *C#N 0.000 claims description 12
125000001153 fluoro group Chemical group F* 0.000 claims description 12
230000008569 process Effects 0.000 claims description 12
239000012528 membrane Substances 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
101150013372 Htr2c gene Proteins 0.000 claims description 10
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 10
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
125000000753 cycloalkyl group Chemical group 0.000 claims description 10
VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical group ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 9
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 9
206010053236 Mixed incontinence Diseases 0.000 claims description 8
125000001072 heteroaryl group Chemical group 0.000 claims description 8
229910052757 nitrogen Inorganic materials 0.000 claims description 8
QZYYPQAYSFBKPW-UHFFFAOYSA-N org 12962 Chemical compound N1=C(Cl)C(C(F)(F)F)=CC=C1N1CCNCC1 QZYYPQAYSFBKPW-UHFFFAOYSA-N 0.000 claims description 8
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 7
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
125000003118 aryl group Chemical group 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
238000012216 screening Methods 0.000 claims description 6
230000004913 activation Effects 0.000 claims description 5
230000027455 binding Effects 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims description 4
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
125000004532 benzofuran-3-yl group Chemical group O1C=C(C2=C1C=CC=C2)* 0.000 claims description 4
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims description 4
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims description 4
125000004551 isoquinolin-3-yl group Chemical group C1=NC(=CC2=CC=CC=C12)* 0.000 claims description 4
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims description 4
125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims description 4
125000004159 quinolin-2-yl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C([H])C(*)=NC2=C1[H] 0.000 claims description 4
125000004548 quinolin-3-yl group Chemical group N1=CC(=CC2=CC=CC=C12)* 0.000 claims description 4
230000000638 stimulation Effects 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 4
125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims description 3
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 3
PHGWDAICBXUJDU-UHFFFAOYSA-N 8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound N1C(=O)C2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 PHGWDAICBXUJDU-UHFFFAOYSA-N 0.000 claims description 3
238000000670 ligand binding assay Methods 0.000 claims description 3
238000004806 packaging method and process Methods 0.000 claims description 3
238000002360 preparation method Methods 0.000 claims description 3
125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims description 3
230000009467 reduction Effects 0.000 claims description 3
125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 claims description 2
125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 claims description 2
125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 claims description 2
125000004510 1,3,4-oxadiazol-5-yl group Chemical group O1C=NN=C1* 0.000 claims description 2
125000004521 1,3,4-thiadiazol-2-yl group Chemical group S1C(=NN=C1)* 0.000 claims description 2
125000004522 1,3,4-thiadiazol-5-yl group Chemical group S1C=NN=C1* 0.000 claims description 2
239000003446 ligand Substances 0.000 claims description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims 48
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
239000000651 prodrug Substances 0.000 claims 12
229940002612 prodrug Drugs 0.000 claims 12
239000012453 solvate Substances 0.000 claims 4
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 2
241000080590 Niso Species 0.000 claims 1
239000011575 calcium Substances 0.000 description 48
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 41
210000003932 urinary bladder Anatomy 0.000 description 34
229940079593 drug Drugs 0.000 description 21
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 19
125000004356 hydroxy functional group Chemical group O* 0.000 description 18
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
210000004027 cell Anatomy 0.000 description 16
230000027939 micturition Effects 0.000 description 16
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 15
238000011049 filling Methods 0.000 description 14
GRFOHUBBUMAJMM-UHFFFAOYSA-N 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide Chemical compound C=1C2=CC=CC=C2N=C(N)C=1CCC(=O)N(C)C1CCCCC1 GRFOHUBBUMAJMM-UHFFFAOYSA-N 0.000 description 12
210000002700 urine Anatomy 0.000 description 12
241001465754 Metazoa Species 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
230000003187 abdominal effect Effects 0.000 description 10
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 9
239000002552 dosage form Substances 0.000 description 9
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 8
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 8
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 8
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 8
241000700159 Rattus Species 0.000 description 8
238000002825 functional assay Methods 0.000 description 8
230000001965 increasing effect Effects 0.000 description 8
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
230000036515 potency Effects 0.000 description 7
229920000858 Cyclodextrin Polymers 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000005557 antagonist Substances 0.000 description 6
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
BRKIIHVUPRCOBS-UHFFFAOYSA-N 2-[(2,3-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1F BRKIIHVUPRCOBS-UHFFFAOYSA-N 0.000 description 5
XRDLYGQZGDDPDQ-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=C(F)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 XRDLYGQZGDDPDQ-UHFFFAOYSA-N 0.000 description 5
PNURVKWAXKYLMY-UHFFFAOYSA-N 2-[(3,5-dichlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC(Cl)=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 PNURVKWAXKYLMY-UHFFFAOYSA-N 0.000 description 5
KTQUGATZSUAOQS-GFCCVEGCSA-N 2-[(3-chlorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C=C(Cl)C=CC=2)=N1 KTQUGATZSUAOQS-GFCCVEGCSA-N 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
229940076279 serotonin Drugs 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
KCLCKODCAVJSID-ZCFIWIBFSA-N (2r)-2-ethylpiperazine-1-carboxylic acid Chemical compound CC[C@@H]1CNCCN1C(O)=O KCLCKODCAVJSID-ZCFIWIBFSA-N 0.000 description 4
BQYVCCOLZOZOFW-LLVKDONJSA-N 2-[(2,5-difluorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C(=CC=C(F)C=2)F)=N1 BQYVCCOLZOZOFW-LLVKDONJSA-N 0.000 description 4
FPPQVDJKEFJQSA-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC(F)=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 FPPQVDJKEFJQSA-UHFFFAOYSA-N 0.000 description 4
UDITUSZOFDATJR-UHFFFAOYSA-N 2-[(3-chlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 UDITUSZOFDATJR-UHFFFAOYSA-N 0.000 description 4
108060003345 Adrenergic Receptor Proteins 0.000 description 4
102000017910 Adrenergic receptor Human genes 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
230000036724 intravesical pressure Effects 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
QIRJIVPBWTXCEE-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine Chemical compound ClC1=CC=CC(CNC=2N=C(C=CN=2)N2CCNCC2)=C1 QIRJIVPBWTXCEE-UHFFFAOYSA-N 0.000 description 4
XIGCMLQZNVYBFC-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine Chemical compound FC1=CC=CC(CNC=2N=C(N=CC=2)N2CCNCC2)=C1 XIGCMLQZNVYBFC-UHFFFAOYSA-N 0.000 description 4
VOARFYJOUYYBBO-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=CN=2)N2CCNCC2)=C1 VOARFYJOUYYBBO-UHFFFAOYSA-N 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000005070 sphincter Anatomy 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
ALWQBVRXXALOIX-UHFFFAOYSA-N 2-[(2-chlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC=C1COC1=NC=CC(N2CCNCC2)=N1 ALWQBVRXXALOIX-UHFFFAOYSA-N 0.000 description 3
RWFXQDJYNCYBMZ-GFCCVEGCSA-N 2-[(3-chlorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C=C(Cl)C=CC=2)=N1 RWFXQDJYNCYBMZ-GFCCVEGCSA-N 0.000 description 3
PCWGGOVOEWHPMG-UHFFFAOYSA-N 2-[(3-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 PCWGGOVOEWHPMG-UHFFFAOYSA-N 0.000 description 3
USDZQWDVSSESIH-UHFFFAOYSA-N 2-[(3-fluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 USDZQWDVSSESIH-UHFFFAOYSA-N 0.000 description 3
KATOHVKJXICHEN-UHFFFAOYSA-N 2-[(3-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 KATOHVKJXICHEN-UHFFFAOYSA-N 0.000 description 3
OMMBWIWJPLKNFD-UHFFFAOYSA-N 2-phenylmethoxy-6-piperazin-1-ylpyrazine Chemical group C=1C=CC=CC=1COC(N=1)=CN=CC=1N1CCNCC1 OMMBWIWJPLKNFD-UHFFFAOYSA-N 0.000 description 3
ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 4-phenylmethoxy-2-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=1)=CC=NC=1N1CCNCC1 ZZGXJWPNJUVOCQ-UHFFFAOYSA-N 0.000 description 3
BKZIGBBKEASYTN-UHFFFAOYSA-N 4-piperazin-1-yl-2-[(2,3,5-trifluorophenyl)methoxy]pyrimidine Chemical compound FC1=CC(F)=C(F)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 BKZIGBBKEASYTN-UHFFFAOYSA-N 0.000 description 3
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010011224 Cough Diseases 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 3
OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 3
101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 description 3
206010046543 Urinary incontinence Diseases 0.000 description 3
210000001015 abdomen Anatomy 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000008186 active pharmaceutical agent Substances 0.000 description 3
235000010980 cellulose Nutrition 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000008602 contraction Effects 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229940088679 drug related substance Drugs 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
230000004907 flux Effects 0.000 description 3
230000006870 function Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
102000045993 human HTR2C Human genes 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
229960001375 lactose Drugs 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
GWGJQKSPIFQZSN-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine Chemical compound ClC1=CC=CC(CNC=2N=C(N=CC=2)N2CCNCC2)=C1 GWGJQKSPIFQZSN-UHFFFAOYSA-N 0.000 description 3
230000035699 permeability Effects 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 3
239000002484 serotonin 2C antagonist Substances 0.000 description 3
239000007921 spray Substances 0.000 description 3
210000003699 striated muscle Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
MRXGFASLDAZMJE-LLVKDONJSA-N 2-[(2,5-dichlorophenyl)methoxy]-4-[(2r)-2-methylpiperazin-1-yl]pyrimidine Chemical compound C[C@@H]1CNCCN1C1=CC=NC(OCC=2C(=CC=C(Cl)C=2)Cl)=N1 MRXGFASLDAZMJE-LLVKDONJSA-N 0.000 description 2
TZZAFXPZDBVHGJ-UHFFFAOYSA-N 2-[(2,5-dichlorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=C(Cl)C(COC=2N=C(C=CN=2)N2CCNCC2)=C1 TZZAFXPZDBVHGJ-UHFFFAOYSA-N 0.000 description 2
SNWOBEHYYUYURQ-UHFFFAOYSA-N 2-[(2,5-dichlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=C(Cl)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 SNWOBEHYYUYURQ-UHFFFAOYSA-N 0.000 description 2
KFSIBDILKOCDLE-UHFFFAOYSA-N 2-[(2-fluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 KFSIBDILKOCDLE-UHFFFAOYSA-N 0.000 description 2
VSMKYRFYLHYLFY-UHFFFAOYSA-N 2-[(3-chlorophenyl)methylsulfanyl]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(CSC=2N=C(C=NC=2)N2CCNCC2)=C1 VSMKYRFYLHYLFY-UHFFFAOYSA-N 0.000 description 2
COQKRZUTHFXRJV-UHFFFAOYSA-N 2-[(3-methoxyphenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 COQKRZUTHFXRJV-UHFFFAOYSA-N 0.000 description 2
AVIQWPWNFJDNIP-UHFFFAOYSA-N 2-[(6-chloropyridin-2-yl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound ClC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=N1 AVIQWPWNFJDNIP-UHFFFAOYSA-N 0.000 description 2
WMZHFOOIFQPPDL-UHFFFAOYSA-N 2-[(6-methylpyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group CC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 WMZHFOOIFQPPDL-UHFFFAOYSA-N 0.000 description 2
KPBGYRGQZIDMFT-UHFFFAOYSA-N 2-benzylsulfanyl-6-piperazin-1-ylpyrazine Chemical group C=1C=CC=CC=1CSC(N=1)=CN=CC=1N1CCNCC1 KPBGYRGQZIDMFT-UHFFFAOYSA-N 0.000 description 2
WEFWVXXUGIKYLH-UHFFFAOYSA-N 2-phenylmethoxy-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=CC=1COC(N=1)=NC=CC=1N1CCNCC1 WEFWVXXUGIKYLH-UHFFFAOYSA-N 0.000 description 2
BTFBHHWABYOSPA-UHFFFAOYSA-N 3-[[(6-piperazin-1-ylpyrazin-2-yl)amino]methyl]benzonitrile Chemical compound N#CC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 BTFBHHWABYOSPA-UHFFFAOYSA-N 0.000 description 2
LIRBEKSOJXQCQB-UHFFFAOYSA-N 4-methyl-2-phenylmethoxy-6-piperazin-1-ylpyrimidine Chemical compound N=1C(C)=CC(N2CCNCC2)=NC=1OCC1=CC=CC=C1 LIRBEKSOJXQCQB-UHFFFAOYSA-N 0.000 description 2
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
229920002785 Croscarmellose sodium Polymers 0.000 description 2
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
108010001441 Phosphopeptides Proteins 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
229920002873 Polyethylenimine Polymers 0.000 description 2
208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
238000007792 addition Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000012131 assay buffer Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzenecarbonitrile Natural products N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
210000001715 carotid artery Anatomy 0.000 description 2
125000001309 chloro group Chemical group Cl* 0.000 description 2
150000001860 citric acid derivatives Chemical class 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
201000003892 detrusor sphincter dyssynergia Diseases 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
229960003132 halothane Drugs 0.000 description 2
230000002440 hepatic effect Effects 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
210000004731 jugular vein Anatomy 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
239000003607 modifier Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
FYWOHRYTOCDGHZ-UHFFFAOYSA-N n-[(3,5-dichlorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound ClC1=CC(Cl)=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 FYWOHRYTOCDGHZ-UHFFFAOYSA-N 0.000 description 2
DIERXLYMJQVEND-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC(F)=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 DIERXLYMJQVEND-UHFFFAOYSA-N 0.000 description 2
VQMSZKDMVHWVFM-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-6-(2-methylpiperazin-1-yl)pyrazin-2-amine Chemical compound CC1CNCCN1C1=CN=CC(NCC=2C=C(Cl)C=CC=2)=N1 VQMSZKDMVHWVFM-UHFFFAOYSA-N 0.000 description 2
PXXBUFCUGLZABH-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-n-(6-piperazin-1-ylpyrazin-2-yl)acetamide Chemical compound C=1N=CC(N2CCNCC2)=NC=1N(C(=O)C)CC1=CC=CC(Cl)=C1 PXXBUFCUGLZABH-UHFFFAOYSA-N 0.000 description 2
XYISMKOEWXHJEE-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 XYISMKOEWXHJEE-UHFFFAOYSA-N 0.000 description 2
UCTDIIVSAPSFRV-UHFFFAOYSA-N n-benzyl-2-piperazin-1-ylpyrimidin-4-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=CC=NC=1N1CCNCC1 UCTDIIVSAPSFRV-UHFFFAOYSA-N 0.000 description 2
SGUBXKWIXLLZPM-UHFFFAOYSA-N n-benzyl-4-piperazin-1-ylpyrimidin-2-amine Chemical compound C=1C=CC=CC=1CNC(N=1)=NC=CC=1N1CCNCC1 SGUBXKWIXLLZPM-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
239000003380 propellant Substances 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
230000000541 pulsatile effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
239000002485 serotonin 2C agonist Substances 0.000 description 2
150000004760 silicates Chemical class 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
206010041232 sneezing Diseases 0.000 description 2
239000002904 solvent Substances 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
238000009423 ventilation Methods 0.000 description 2
GFDFZTFQPIBNSQ-UHFFFAOYSA-N (+)-homo-18-epiormosanine Natural products C1C(C23)CCCN3CN3CCCCC3C32CN2CCCCC2C1C3 GFDFZTFQPIBNSQ-UHFFFAOYSA-N 0.000 description 1
KALDYHARSPUPKC-GFCCVEGCSA-N (2,6-difluoro-4-prop-2-ynoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC1=C(F)C=C(OCC#C)C=C1F KALDYHARSPUPKC-GFCCVEGCSA-N 0.000 description 1
OTZUXDKPQPFVDM-GFCCVEGCSA-N (2-chloro-6-fluoro-4-prop-2-ynoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC1=C(F)C=C(OCC#C)C=C1Cl OTZUXDKPQPFVDM-GFCCVEGCSA-N 0.000 description 1
RUCPUQIUIHZKIW-GFCCVEGCSA-N (2-chloro-6-fluoro-4-propoxyphenyl)methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound ClC1=CC(OCCC)=CC(F)=C1COC(=O)N1[C@H](CC)CNCC1 RUCPUQIUIHZKIW-GFCCVEGCSA-N 0.000 description 1
XFWLERLAWZDCRZ-CQSZACIVSA-N (2-fluoro-5-pentoxyphenyl)methyl (2r)-2-methylpiperazine-1-carboxylate Chemical compound CCCCCOC1=CC=C(F)C(COC(=O)N2[C@@H](CNCC2)C)=C1 XFWLERLAWZDCRZ-CQSZACIVSA-N 0.000 description 1
MLBHFBKZUPLWBD-ZETCQYMHSA-N (2S)-1-[3-(trifluoromethyl)phenyl]-2-propanamine Chemical compound C[C@H](N)CC1=CC=CC(C(F)(F)F)=C1 MLBHFBKZUPLWBD-ZETCQYMHSA-N 0.000 description 1
PRWOYVUMSZQUCT-OAHLLOKOSA-N (2r)-2-[[4-(difluoromethoxy)phenyl]methyl]-2-ethylpiperazine-1-carboxylic acid Chemical compound C=1C=C(OC(F)F)C=CC=1C[C@]1(CC)CNCCN1C(O)=O PRWOYVUMSZQUCT-OAHLLOKOSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
OBQZQQHWYDPMDY-VIFPVBQESA-N (2s)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)propan-2-amine Chemical compound C1=C2OCCC2=C2N(C[C@@H](N)C)CCC2=C1 OBQZQQHWYDPMDY-VIFPVBQESA-N 0.000 description 1
UTLBGXQIQOXKNB-VIFPVBQESA-N (2s)-1-(7,8-dihydro-6h-pyrido[4,3-b]pyrrolizin-5-yl)propan-2-amine Chemical compound C12=CN=CC=C2C(C[C@@H](N)C)=C2N1CCC2 UTLBGXQIQOXKNB-VIFPVBQESA-N 0.000 description 1
JYSVKYGPBNOLPK-VIFPVBQESA-N (2s)-1-(7-fluoro-8-methoxy-2,3-dihydro-1h-cyclopenta[b]indol-4-yl)propan-2-amine Chemical compound COC1=C(F)C=CC2=C1C(CCC1)=C1N2C[C@H](C)N JYSVKYGPBNOLPK-VIFPVBQESA-N 0.000 description 1
TZKHUTNZGIQFHG-QMMMGPOBSA-N (2s)-1-(7-methoxythieno[2,3-g]indazol-1-yl)propan-2-amine Chemical compound S1C(OC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 TZKHUTNZGIQFHG-QMMMGPOBSA-N 0.000 description 1
PHGWDAICBXUJDU-SNVBAGLBSA-N (4ar)-8,9-dichloro-1,2,3,4,4a,6-hexahydropyrazino[1,2-a]quinoxalin-5-one Chemical compound C([C@@H]1C(=O)N2)NCCN1C1=C2C=C(Cl)C(Cl)=C1 PHGWDAICBXUJDU-SNVBAGLBSA-N 0.000 description 1
HAZWRUAJTCVCEE-MRVPVSSYSA-N (4r)-4-methyl-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=CC(C(F)(F)F)=C2N3[C@H](C)CNCC3=CC2=C1 HAZWRUAJTCVCEE-MRVPVSSYSA-N 0.000 description 1
FVONZVAYLZSBOJ-SECBINFHSA-N (4r)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C2CNC[C@@H](C)N2C2=C1C=C(F)C=C2CC FVONZVAYLZSBOJ-SECBINFHSA-N 0.000 description 1
QCCLCOBTVCROQM-MRVPVSSYSA-N (4r)-7-chloro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C(Cl)C=C2N3[C@H](C)CNCC3=CC2=C1 QCCLCOBTVCROQM-MRVPVSSYSA-N 0.000 description 1
PLPARSCPGGUWDI-SECBINFHSA-N (4r)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound FC1=C(C)C=C2N3[C@H](C)CNCC3=CC2=C1 PLPARSCPGGUWDI-SECBINFHSA-N 0.000 description 1
RXFLPRDWCDWXHV-FUTAKVPZSA-N (e)-n,n-dimethyl-3-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]prop-2-en-1-amine Chemical compound C[C@@H]1CNCCN1C1=NC=CN=C1OCCOC1=CC=CN=C1\C=C\CN(C)C RXFLPRDWCDWXHV-FUTAKVPZSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
MMWCIQZXVOZEGG-UHFFFAOYSA-N 1,4,5-IP3 Natural products OC1C(O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(O)C1OP(O)(O)=O MMWCIQZXVOZEGG-UHFFFAOYSA-N 0.000 description 1
ASYRZEICFCXPBF-UHFFFAOYSA-N 1-(5,6-difluoro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(CC(N)C)CCC2=C1 ASYRZEICFCXPBF-UHFFFAOYSA-N 0.000 description 1
DRLGTCNDEBEPQP-UHFFFAOYSA-N 1-(5,6-difluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(F)C=C2N(CC(N)C)N=C(C)C2=C1 DRLGTCNDEBEPQP-UHFFFAOYSA-N 0.000 description 1
SGEUVUWZSAXGFY-UHFFFAOYSA-N 1-(5-bromo-2h-indazol-3-yl)propan-2-amine Chemical compound C1=C(Br)C=C2C(CC(N)C)=NNC2=C1 SGEUVUWZSAXGFY-UHFFFAOYSA-N 0.000 description 1
CFOYPOXDKROVPX-UHFFFAOYSA-N 1-(5-chloro-1-methylindazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NN(C)C2=C1 CFOYPOXDKROVPX-UHFFFAOYSA-N 0.000 description 1
SBKWOWHPSMTOBC-UHFFFAOYSA-N 1-(5-chloro-1-propan-2-ylindazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NN(C(C)C)C2=C1 SBKWOWHPSMTOBC-UHFFFAOYSA-N 0.000 description 1
HFVVDQSCZPXWSY-UHFFFAOYSA-N 1-(5-chloro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound ClC1=CC=C2N(CC(N)C)CCC2=C1 HFVVDQSCZPXWSY-UHFFFAOYSA-N 0.000 description 1
RIGRKJDNTIKRQD-UHFFFAOYSA-N 1-(5-chloro-2h-indazol-3-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2C(CC(N)C)=NNC2=C1 RIGRKJDNTIKRQD-UHFFFAOYSA-N 0.000 description 1
KZFPTLZBQZDFHT-UHFFFAOYSA-N 1-(5-fluoro-6-iodo-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(I)C=C2N(CC(N)C)CCC2=C1 KZFPTLZBQZDFHT-UHFFFAOYSA-N 0.000 description 1
KATMBNIBQAWHQJ-UHFFFAOYSA-N 1-(5-fluoro-6-methyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(C)C=C2N(CC(N)C)CCC2=C1 KATMBNIBQAWHQJ-UHFFFAOYSA-N 0.000 description 1
IGAAICGMRRWZJW-UHFFFAOYSA-N 1-(5-fluoro-6-methylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound C1=C(F)C(SC)=CC2=C1CCN2CC(C)N IGAAICGMRRWZJW-UHFFFAOYSA-N 0.000 description 1
RJYKMNOUJHRYTQ-UHFFFAOYSA-N 1-(5-methoxy-1-methylindazol-3-yl)propan-2-amine Chemical compound COC1=CC=C2N(C)N=C(CC(C)N)C2=C1 RJYKMNOUJHRYTQ-UHFFFAOYSA-N 0.000 description 1
QGDUUJDJXSDKCP-UHFFFAOYSA-N 1-(6-bromo-3-ethylindazol-1-yl)propan-2-amine Chemical compound BrC1=CC=C2C(CC)=NN(CC(C)N)C2=C1 QGDUUJDJXSDKCP-UHFFFAOYSA-N 0.000 description 1
XEAADXLKWPGODO-UHFFFAOYSA-N 1-(6-chloro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound C1=C(Cl)C=C2N(CC(N)C)CCC2=C1 XEAADXLKWPGODO-UHFFFAOYSA-N 0.000 description 1
OKTLNQVSINRJKA-UHFFFAOYSA-N 1-(6-chloro-5-fluoro-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)CCC2=C1 OKTLNQVSINRJKA-UHFFFAOYSA-N 0.000 description 1
PKGIAAHUVWWFPM-UHFFFAOYSA-N 1-(6-chloro-5-fluoro-3-methylindazol-1-yl)propan-2-amine Chemical compound FC1=C(Cl)C=C2N(CC(N)C)N=C(C)C2=C1 PKGIAAHUVWWFPM-UHFFFAOYSA-N 0.000 description 1
ZATISPXVUJXJRK-UHFFFAOYSA-N 1-(6-ethylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CCSC1=CC=C2CCN(CC(C)N)C2=C1 ZATISPXVUJXJRK-UHFFFAOYSA-N 0.000 description 1
ALMFEOBYDZUSIC-UHFFFAOYSA-N 1-(6-methoxy-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound COC1=CC=C2CCN(CC(C)N)C2=C1 ALMFEOBYDZUSIC-UHFFFAOYSA-N 0.000 description 1
WMYZYDUOEKWORM-UHFFFAOYSA-N 1-(6-methoxy-3-methylindazol-1-yl)propan-2-amine Chemical compound COC1=CC=C2C(C)=NN(CC(C)N)C2=C1 WMYZYDUOEKWORM-UHFFFAOYSA-N 0.000 description 1
MBDXWHFBIOEOHU-UHFFFAOYSA-N 1-(6-methylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CSC1=CC=C2CCN(CC(C)N)C2=C1 MBDXWHFBIOEOHU-UHFFFAOYSA-N 0.000 description 1
SSDXLHXTFQHCNR-UHFFFAOYSA-N 1-(6-propylsulfanyl-2,3-dihydroindol-1-yl)propan-2-amine Chemical compound CCCSC1=CC=C2CCN(CC(C)N)C2=C1 SSDXLHXTFQHCNR-UHFFFAOYSA-N 0.000 description 1
OCJCKHPFQNWROT-UHFFFAOYSA-N 1-[3-ethyl-6-(trifluoromethyl)indazol-1-yl]propan-2-amine Chemical compound FC(F)(F)C1=CC=C2C(CC)=NN(CC(C)N)C2=C1 OCJCKHPFQNWROT-UHFFFAOYSA-N 0.000 description 1
HMGZRIYJGAGANE-UHFFFAOYSA-N 1-[5-fluoro-6-(trifluoromethyl)-2,3-dihydroindol-1-yl]propan-2-amine Chemical compound FC1=C(C(F)(F)F)C=C2N(CC(N)C)CCC2=C1 HMGZRIYJGAGANE-UHFFFAOYSA-N 0.000 description 1
OKHMLNQDEKKFRY-UHFFFAOYSA-N 1-[6-(trifluoromethyl)-2,3-dihydroindol-1-yl]propan-2-amine Chemical compound C1=C(C(F)(F)F)C=C2N(CC(N)C)CCC2=C1 OKHMLNQDEKKFRY-UHFFFAOYSA-N 0.000 description 1
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 1
DUHRAVUGWQLFKQ-UHFFFAOYSA-N 2-(2-methylpiperazin-1-yl)-6-[(6-methylpyridin-2-yl)methoxy]pyrazine Chemical group CC1CNCCN1C1=CN=CC(OCC=2N=C(C)C=CC=2)=N1 DUHRAVUGWQLFKQ-UHFFFAOYSA-N 0.000 description 1
LVIRPARUNBTHAR-UHFFFAOYSA-N 2-(6-chloro-2,3-dihydroindol-1-yl)ethanamine Chemical compound C1=C(Cl)C=C2N(CCN)CCC2=C1 LVIRPARUNBTHAR-UHFFFAOYSA-N 0.000 description 1
RNWQKUXWKDGPTF-UHFFFAOYSA-N 2-[(2,5-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=C(F)C(COC=2N=C(C=NC=2)N2CCNCC2)=C1 RNWQKUXWKDGPTF-UHFFFAOYSA-N 0.000 description 1
FUFZPBIDXGUMNR-GFCCVEGCSA-N 2-[(2-chlorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C(=CC=CC=2)Cl)=N1 FUFZPBIDXGUMNR-GFCCVEGCSA-N 0.000 description 1
OOUPQSFTNBGJPD-UHFFFAOYSA-N 2-[(2-chlorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 OOUPQSFTNBGJPD-UHFFFAOYSA-N 0.000 description 1
FFBVDPBCXIBGLD-UHFFFAOYSA-N 2-[(2-methylphenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group CC1=CC=CC=C1COC1=CN=CC(N2CCNCC2)=N1 FFBVDPBCXIBGLD-UHFFFAOYSA-N 0.000 description 1
HQRWFZROVHEFSD-UHFFFAOYSA-N 2-[(3,4-difluorophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group C1=C(F)C(F)=CC=C1COC1=CN=CC(N2CCNCC2)=N1 HQRWFZROVHEFSD-UHFFFAOYSA-N 0.000 description 1
USWXRXCXADVWNZ-UHFFFAOYSA-N 2-[(3,5-difluorophenyl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound FC1=CC(F)=CC(COC=2N=C(C=CN=2)N2CCNCC2)=C1 USWXRXCXADVWNZ-UHFFFAOYSA-N 0.000 description 1
JPAOODDUOPDRLG-UHFFFAOYSA-N 2-[(3-bromophenyl)methoxy]-6-piperazin-1-ylpyrazine Chemical group BrC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 JPAOODDUOPDRLG-UHFFFAOYSA-N 0.000 description 1
UXNABWNPOYOUBM-GFCCVEGCSA-N 2-[(3-fluorophenyl)methoxy]-6-[(2r)-2-methylpiperazin-1-yl]pyrazine Chemical group C[C@@H]1CNCCN1C1=CN=CC(OCC=2C=C(F)C=CC=2)=N1 UXNABWNPOYOUBM-GFCCVEGCSA-N 0.000 description 1
FOXDXBPMVWHWLN-UHFFFAOYSA-N 2-[(6-chloropyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 FOXDXBPMVWHWLN-UHFFFAOYSA-N 0.000 description 1
UFRQWANAVAZVHS-UHFFFAOYSA-N 2-[(6-fluoropyridin-2-yl)methoxy]-6-piperazin-1-ylpyrazine Chemical group FC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=N1 UFRQWANAVAZVHS-UHFFFAOYSA-N 0.000 description 1
WNIDFMGNFAYMIV-UHFFFAOYSA-N 2-[(6-methylpyridin-2-yl)methoxy]-4-piperazin-1-ylpyrimidine Chemical compound CC1=CC=CC(COC=2N=C(C=CN=2)N2CCNCC2)=N1 WNIDFMGNFAYMIV-UHFFFAOYSA-N 0.000 description 1
JMIKUXDRIYZMFK-UHFFFAOYSA-N 2-[1-(2-chlorophenyl)ethoxy]-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC=C(Cl)C=1C(C)OC(N=1)=NC=CC=1N1CCNCC1 JMIKUXDRIYZMFK-UHFFFAOYSA-N 0.000 description 1
WUDGUDALTCJVFI-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)ethoxy]-4-methyl-6-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(Cl)=CC=1C(C)OC(N=1)=NC(C)=CC=1N1CCNCC1 WUDGUDALTCJVFI-UHFFFAOYSA-N 0.000 description 1
PFKJMESILVYLQS-UHFFFAOYSA-N 2-[1-(3-chlorophenyl)ethoxy]-4-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(Cl)=CC=1C(C)OC(N=1)=NC=CC=1N1CCNCC1 PFKJMESILVYLQS-UHFFFAOYSA-N 0.000 description 1
AIFVACPLVHXPME-UHFFFAOYSA-N 2-[1-(3-fluorophenyl)ethoxy]-4-methyl-6-piperazin-1-ylpyrimidine Chemical compound C=1C=CC(F)=CC=1C(C)OC(N=1)=NC(C)=CC=1N1CCNCC1 AIFVACPLVHXPME-UHFFFAOYSA-N 0.000 description 1
UXACGMNLBLFPQV-UHFFFAOYSA-N 2-[2-(3-chlorophenyl)ethoxy]-6-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(CCOC=2N=C(C=NC=2)N2CCNCC2)=C1 UXACGMNLBLFPQV-UHFFFAOYSA-N 0.000 description 1
XFVFOSGWIJHHPO-CQSZACIVSA-N 2-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]oxyethanamine Chemical compound C[C@@H]1CNCCN1C1=NC=CN=C1OCCOC1=CC=CN=C1OCCN XFVFOSGWIJHHPO-CQSZACIVSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
PXMNBTNIDJTYFM-NSHDSACASA-N 2-[[4-[(2s)-2-aminopropyl]-2,3-dihydro-1h-pyrrolo[1,2-a]indol-6-yl]oxy]ethanol Chemical compound C12=CC=C(OCCO)C=C2C(C[C@@H](N)C)=C2N1CCC2 PXMNBTNIDJTYFM-NSHDSACASA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
ZJRJISIATULYIL-UHFFFAOYSA-N 2-chloro-3-[(3-chlorophenyl)methoxy]-5-piperazin-1-ylpyrazine Chemical group ClC1=CC=CC(COC=2C(=NC=C(N=2)N2CCNCC2)Cl)=C1 ZJRJISIATULYIL-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
HCGFLVDMFDHYJD-UHFFFAOYSA-N 2-piperazin-1-ylpyrazine Chemical group C1CNCCN1C1=CN=CC=N1 HCGFLVDMFDHYJD-UHFFFAOYSA-N 0.000 description 1
XCQFQGFHDMRIJB-UHFFFAOYSA-N 3-[(3-chlorophenyl)methoxy]-1-oxido-5-piperazin-1-ylpyrazin-1-ium Chemical compound N=1C(N2CCNCC2)=C[N+]([O-])=CC=1OCC1=CC=CC(Cl)=C1 XCQFQGFHDMRIJB-UHFFFAOYSA-N 0.000 description 1
CVXKDULHYNQXGA-UHFFFAOYSA-N 3-[(3-chlorophenyl)methoxy]-2-fluoro-5-piperazin-1-ylpyrazine Chemical group FC1=NC=C(N2CCNCC2)N=C1OCC1=CC=CC(Cl)=C1 CVXKDULHYNQXGA-UHFFFAOYSA-N 0.000 description 1
LEXVVQNKFIXJOP-UHFFFAOYSA-N 3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]aniline Chemical compound NC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 LEXVVQNKFIXJOP-UHFFFAOYSA-N 0.000 description 1
UXJDGSAVALXBTN-UHFFFAOYSA-N 3-[(6-piperazin-1-ylpyrazin-2-yl)oxymethyl]benzonitrile Chemical compound N#CC1=CC=CC(COC=2N=C(C=NC=2)N2CCNCC2)=C1 UXJDGSAVALXBTN-UHFFFAOYSA-N 0.000 description 1
CPVBWHBWLRSCHV-UHFFFAOYSA-N 4-[(2-methoxyphenyl)methoxy]-2-piperazin-1-ylpyrimidine Chemical compound COC1=CC=CC=C1COC1=CC=NC(N2CCNCC2)=N1 CPVBWHBWLRSCHV-UHFFFAOYSA-N 0.000 description 1
CXOHCQFVEIUPEW-UHFFFAOYSA-N 4-piperazin-1-yl-2-(pyridin-2-ylmethoxy)pyrimidine Chemical compound C=1C=CC=NC=1COC(N=1)=NC=CC=1N1CCNCC1 CXOHCQFVEIUPEW-UHFFFAOYSA-N 0.000 description 1
229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 1
108091005479 5-HT2 receptors Proteins 0.000 description 1
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
102000035037 5-HT3 receptors Human genes 0.000 description 1
108091005477 5-HT3 receptors Proteins 0.000 description 1
101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
PMZMPGDSRIYTDF-UHFFFAOYSA-N 6-bromo-8-(2,4-dichlorophenyl)-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical compound ClC1=CC(Cl)=CC=C1C(C=C1Br)=CC2=C1NC1CCNCC12 PMZMPGDSRIYTDF-UHFFFAOYSA-N 0.000 description 1
DYCDNKQNLQYZCD-UHFFFAOYSA-N 8,9-dichloro-2,3,4,4a,5,6-hexahydro-1h-pyrazino[1,2-a]quinoxaline Chemical compound N1CC2CNCCN2C2=C1C=C(Cl)C(Cl)=C2 DYCDNKQNLQYZCD-UHFFFAOYSA-N 0.000 description 1
OGVIBOYOTLEICI-UHFFFAOYSA-N 8-(2,4-dichlorophenyl)-2,3,4,4a,5,9b-hexahydro-1h-pyrido[4,3-b]indole Chemical compound ClC1=CC(Cl)=CC=C1C1=CC=C(NC2C3CNCC2)C3=C1 OGVIBOYOTLEICI-UHFFFAOYSA-N 0.000 description 1
102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
206010004954 Birth trauma Diseases 0.000 description 1
KSHLDNKSBYMDQG-UHFFFAOYSA-N C1NCCC(N2CCOC(=C32)N=2)C1C3=CC=2C1=CC=CC=C1 Chemical compound C1NCCC(N2CCOC(=C32)N=2)C1C3=CC=2C1=CC=CC=C1 KSHLDNKSBYMDQG-UHFFFAOYSA-N 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
DYUXHGLOHHQSDJ-UHFFFAOYSA-N ClC1=CC(Cl)=CC=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 Chemical compound ClC1=CC(Cl)=CC=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 DYUXHGLOHHQSDJ-UHFFFAOYSA-N 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
MMWCIQZXVOZEGG-XJTPDSDZSA-N D-myo-Inositol 1,4,5-trisphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H](O)[C@@H]1OP(O)(O)=O MMWCIQZXVOZEGG-XJTPDSDZSA-N 0.000 description 1
208000019505 Deglutition disease Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
101000617550 Dictyostelium discoideum Presenilin-A Proteins 0.000 description 1
102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
239000004150 EU approved colour Substances 0.000 description 1
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
SCRZCUNDEHVBDQ-MRXNPFEDSA-N FC1=CC(OCCC)=CC(F)=C1C[C@@]1(C)N(C(O)=O)CCNC1 Chemical compound FC1=CC(OCCC)=CC(F)=C1C[C@@]1(C)N(C(O)=O)CCNC1 SCRZCUNDEHVBDQ-MRXNPFEDSA-N 0.000 description 1
RXSKHZZJWNOXAI-UHFFFAOYSA-N FC1=CC=CC(F)=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 Chemical compound FC1=CC=CC(F)=C1C1=CC(C2C(CCNC2)N2CCO3)=C2C3=N1 RXSKHZZJWNOXAI-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
GFDFZTFQPIBNSQ-LDIYZUBKSA-N Homoormosanine Natural products N12[C@H]3[C@H](C[C@H]4[C@@H]5N(C[C@@]3([C@@H]3N(C1)CCCC3)C4)CCCC5)CCC2 GFDFZTFQPIBNSQ-LDIYZUBKSA-N 0.000 description 1
101150039275 Htr1f gene Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
235000006679 Mentha X verticillata Nutrition 0.000 description 1
235000002899 Mentha suaveolens Nutrition 0.000 description 1
235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
OTJOPJYJJAZRSC-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-2-piperazin-1-ylpyrimidin-4-amine hydrochloride Chemical compound Cl.Clc1cccc(CNc2ccnc(n2)N2CCNCC2)c1 OTJOPJYJJAZRSC-UHFFFAOYSA-N 0.000 description 1
YUBVDAKUPGXFTL-UHFFFAOYSA-N N-[(3-chlorophenyl)methyl]-4-piperazin-1-ylpyrimidin-2-amine hydrochloride Chemical compound Cl.Clc1cccc(CNc2nccc(n2)N2CCNCC2)c1 YUBVDAKUPGXFTL-UHFFFAOYSA-N 0.000 description 1
DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
108010067902 Peptide Library Proteins 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
102000003923 Protein Kinase C Human genes 0.000 description 1
108090000315 Protein Kinase C Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
241000906446 Theraps Species 0.000 description 1
102000014384 Type C Phospholipases Human genes 0.000 description 1
108010079194 Type C Phospholipases Proteins 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
AZLIYAXCQAFORZ-CYBMUJFWSA-N [4-(cyclopropylmethoxy)-2,6-difluorophenyl]methyl (2r)-2-ethylpiperazine-1-carboxylate Chemical compound CC[C@@H]1CNCCN1C(=O)OCC(C(=C1)F)=C(F)C=C1OCC1CC1 AZLIYAXCQAFORZ-CYBMUJFWSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
235000010358 acesulfame potassium Nutrition 0.000 description 1
229960004998 acesulfame potassium Drugs 0.000 description 1
239000000619 acesulfame-K Substances 0.000 description 1
QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000000695 adrenergic alpha-agonist Substances 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000004203 carnauba wax Substances 0.000 description 1
235000013869 carnauba wax Nutrition 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000004040 coloring Methods 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
230000037020 contractile activity Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
238000009109 curative therapy Methods 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
238000010410 dusting Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
239000006274 endogenous ligand Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000006481 glucose medium Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000011554 guinea pig model Methods 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
101150075901 htr2 gene Proteins 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
PNDZEEPOYCVIIY-UHFFFAOYSA-N indo-1 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C=2N=C3[CH]C(=CC=C3C=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 PNDZEEPOYCVIIY-UHFFFAOYSA-N 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
GFDFZTFQPIBNSQ-WSBLSWJJSA-N jamine Chemical compound C([C@H]([C@H]12)C3)CCN2CN2CCCC[C@@H]2[C@]21CN1CCCC[C@@H]1[C@H]3C2 GFDFZTFQPIBNSQ-WSBLSWJJSA-N 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960003955 mianserin Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
210000001589 microsome Anatomy 0.000 description 1
230000036453 micturition reflex Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
IDFANOPDMXWIOP-UHFFFAOYSA-N n,n-dimethylpentan-1-amine Chemical compound CCCCCN(C)C IDFANOPDMXWIOP-UHFFFAOYSA-N 0.000 description 1
NXTBEUAMGPLPKC-UHFFFAOYSA-N n-[(2,3-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1F NXTBEUAMGPLPKC-UHFFFAOYSA-N 0.000 description 1
OQZJOFWBSRLCML-UHFFFAOYSA-N n-[(2,5-difluorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound FC1=CC=C(F)C(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 OQZJOFWBSRLCML-UHFFFAOYSA-N 0.000 description 1
KKGJUZHECNHLDO-UHFFFAOYSA-N n-[(3-chlorophenyl)methyl]-6-piperazin-1-ylpyrazin-2-amine Chemical compound ClC1=CC=CC(CNC=2N=C(C=NC=2)N2CCNCC2)=C1 KKGJUZHECNHLDO-UHFFFAOYSA-N 0.000 description 1
MEDBUZAILMLXCO-OAHLLOKOSA-N n-methyl-2-[3-[2-[3-[(2r)-2-methylpiperazin-1-yl]pyrazin-2-yl]oxyethoxy]pyridin-2-yl]oxyethanamine Chemical compound CNCCOC1=NC=CC=C1OCCOC1=NC=CN=C1N1[C@H](C)CNCC1 MEDBUZAILMLXCO-OAHLLOKOSA-N 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
238000009806 oophorectomy Methods 0.000 description 1
229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000036407 pain Effects 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000019809 paraffin wax Nutrition 0.000 description 1
229960001779 pargyline Drugs 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
238000011422 pharmacological therapy Methods 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
210000003689 pubic bone Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
229940080313 sodium starch Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
208000020431 spinal cord injury Diseases 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
229940127230 sympathomimetic drug Drugs 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000001839 systemic circulation Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000028016 temperature homeostasis Effects 0.000 description 1
125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
210000003708 urethra Anatomy 0.000 description 1
QGRQJMXAQYGAKK-UHFFFAOYSA-N ver-3323 Chemical compound C1=C(Br)C=C2N(CC(N)C)CCC2=C1 QGRQJMXAQYGAKK-UHFFFAOYSA-N 0.000 description 1
238000005406 washing Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200507158A 2003-04-25 2005-09-06 Treatment of incontinence with 5HTC2 agonists ZA200507158B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB0309533		2003-04-25

Publications (1)

Publication Number	Publication Date
ZA200507158B true ZA200507158B (en)	2006-11-29

Family

ID=33397006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200507158A ZA200507158B (en)	2003-04-25	2005-09-06	Treatment of incontinence with 5HTC2 agonists

Country Status (13)

Country	Link
EP (2)	EP1620081A2 (de)
JP (2)	JP2006524679A (de)
KR (3)	KR20100103726A (de)
CN (1)	CN1780612B (de)
AU (2)	AU2004233745B2 (de)
BR (1)	BRPI0409730A (de)
CA (2)	CA2670067A1 (de)
CL (1)	CL2004000826A1 (de)
MX (1)	MXPA05011410A (de)
MY (1)	MY142857A (de)
TW (1)	TW200426142A (de)
WO (1)	WO2004096196A2 (de)
ZA (1)	ZA200507158B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5173190B2 (ja)	2004-08-25	2013-03-27	武田薬品工業株式会社	腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法
US20060258712A1 (en) *	2005-04-24	2006-11-16	Wyeth	Methods for modulating bladder function
US20080234280A1 (en) *	2005-08-01	2008-09-25	Mcmurray Gordon	Use of Mc4 Receptor Agonist Compounds
EP2727585A1 (de)	2006-05-16	2014-05-07	Takeda Pharmaceutical Company Limited	In-vivo Screening-Methode
EP2039695A4 (de)	2006-07-11	2010-09-15	Takeda Pharmaceutical	Bicyclische heterocylische verbindung und deren verwendung
EP2123644B1 (de)	2007-03-07	2014-12-17	Takeda Pharmaceutical Company Limited	Benzoxazepin-derivate und deren anwendung
WO2009063993A1 (ja) *	2007-11-15	2009-05-22	Takeda Pharmaceutical Company Limited	縮合ピリジン誘導体およびその用途
EP2789338A3 (de)	2007-11-15	2015-01-14	Takeda Pharmaceutical Company Limited	Kondensiertes Pyridinderivat und seine Verwendung
WO2009063991A1 (ja)	2007-11-15	2009-05-22	Takeda Pharmaceutical Company Limited	ピリドオキサゼピン誘導体およびその用途
EA021079B1 (ru)	2009-06-15	2015-03-31	Такеда Фармасьютикал Компани Лимитед	Производные пиразинооксазепина
EP2510949A4 (de)	2009-12-11	2013-11-13	Astellas Pharma Inc	Therapeutikum für fibromyalgie
WO2012002583A1 (en) *	2010-07-02	2012-01-05	Vanderbilt University	Method for treating schizophrenia and related diseases with a combination therapy
JP6198715B2 (ja)	2012-03-06	2017-09-20	武田薬品工業株式会社	三環性化合物
US20210052600A1 (en)	2017-12-27	2021-02-25	Takeda Pharmaceutical Company Limited	Therapeutic agents for stress urinary incontinence and incotinence of feces

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CA2044854A1 (en)	1990-07-19	1992-01-20	Hong-I Chen	Method for preventing or treating urinary incontinence
EP0572863A1 (de)	1992-06-05	1993-12-08	F. Hoffmann-La Roche Ag	ZNS Pyrazinoindole
TW334423B (en)	1993-10-22	1998-06-21	Hoffmann La Roche	Tricyclic 1-aminoethylpyrrole-derivatives
TW270114B (de)	1993-10-22	1996-02-11	Hoffmann La Roche
IT1282705B1 (it)	1996-02-28	1998-03-31	Recordati Chem Pharm	Uso di antagonisti del recettore serotoninergico 5-ht\|a per il trattamento dell'incontinenza urinaria
WO1998030548A1 (en)	1997-01-13	1998-07-16	Yamanouchi Pharmaceutical Co., Ltd.	5-HT2c RECEPTOR AGONISTS AND AMINOALKYLINDAZOLE DERIVATIVES
WO1998033504A1 (en)	1997-02-03	1998-08-06	Akzo Nobel N.V.	Treatment of urinary incontinence
ATE250573T1 (de)	1997-02-25	2003-10-15	Akzo Nobel Nv	Azetidin- und pyrrolidinderivate
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
AU727654B2 (en)	1997-06-13	2000-12-21	Yamanouchi Pharmaceutical Co., Ltd.	Tricyclic pyrazole derivative
RU2198873C2 (ru) *	1998-02-26	2003-02-20	Акцо Нобель Н.В.	Производные азетидина и пирролидина
AU4037699A (en)	1998-05-08	1999-11-29	Akzo Nobel N.V.	Novel aryl-hydro naphthalenal kanamines
GB9819019D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds II
GB9819035D0 (en)	1998-09-01	1998-10-28	Cerebrus Res Ltd	Chemical compounds VII
GB9819032D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds IV
GB9819020D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds III
GB9819033D0 (en)	1998-09-01	1998-10-28	Cerebrus Ltd	Chemical compounds VI
GB9820767D0 (en)	1998-09-23	1998-11-18	Cerebrus Ltd	Chemical compounds VIII
AU1738900A (en)	1998-11-19	2000-06-05	Nortran Pharmaceuticals Inc.	Serotonin ligands as pro-erectile compounds
NZ512765A (en)	1998-12-17	2003-10-31	Wyeth Corp	2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists
JP2002535396A (ja)	1999-01-27	2002-10-22	イーライ・リリー・アンド・カンパニー	セロトニン（５−ｈｔ（２ｃ））アゴニストとしてのアミノアルキルベンゾフラン類
WO2000069437A1 (en)	1999-05-18	2000-11-23	Synaptic Pharmaceutical Corporation	Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder
WO2000076984A2 (en) *	1999-05-21	2000-12-21	Biovitrum Ab	Novel compounds, their use and preparation
SE9901884D0 (sv) *	1999-05-21	1999-05-21	Pharmacia & Upjohn Ab	Novel compounds their use and preparation
US6465467B1 (en) *	1999-05-21	2002-10-15	Biovitrum Ab	Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
ATE277048T1 (de)	1999-06-15	2004-10-15	Bristol Myers Squibb Pharma Co	Substituierte hetercyclisch kondensierte gamma carboline
US6399826B1 (en) *	1999-08-11	2002-06-04	Sepracor Inc.	Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
GB9918962D0 (en)	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxii
GB9918965D0 (en)	1999-08-11	1999-10-13	Cerebrus Ltd	Chemical compounds xxi
US20030004207A1 (en)	1999-11-29	2003-01-02	Douglas A. Craig	Use of compounds which activate a 5-ht receptor to treat urinary incontinence
EP1132389A1 (de)	2000-03-06	2001-09-12	Vernalis Research Limited	Neue Azaindolyl-Derivate für die Behandlung von Fettleibigheit
CA2402472A1 (en)	2000-03-14	2001-10-04	Michael Dalton Ennis	2,3,4,5-tetrahydro-1h-¬1,4\|diazepino¬1,7a\|indole compounds
AU5256301A (en)	2000-04-28	2001-11-12	Yamanouchi Pharmaceutical Co., Ltd.	Froindazole derivative
SE0002754D0 (sv) *	2000-07-21	2000-07-21	Pharmacia & Upjohn Ab	New pharmaceutical combination formulation and method of treatment with the combination
SE0004245D0 (sv)	2000-11-20	2000-11-20	Pharmacia Ab	Novel compounds and their use
NZ525699A (en) *	2000-11-20	2005-03-24	Biovitrum Ab	Piperazinylpyrazines compounds as antagonists of serotonin 5-HT2 receptor
CA2448729A1 (en) *	2000-11-20	2002-05-23	Biovitrum Ab	Piperazinyl and piperidyl substituted heterocyclic compounds
US6498184B2 (en) *	2000-12-05	2002-12-24	Akzo Nobel N.V.	Serotonergic compound for a method of treatment of hot flushes in post-menopausal women
GB0030710D0 (en)	2000-12-15	2001-01-31	Hoffmann La Roche	Piperazine derivatives
SK7042003A3 (en)	2000-12-20	2004-07-07	Bristol Myers Squibb Co	Substituted pyridoindoles as serotonin agonists and antagonists
JP4386639B2 (ja)	2000-12-20	2009-12-16	ブリストル−マイヤーズスクイブカンパニー	セロトニンアゴニストおよびアンタゴニストとしての置換されたピロロキノリン化合物およびピリドキノリン化合物
KR100539143B1 (ko)	2000-12-27	2005-12-26	에프. 호프만-라 로슈 아게	인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
GB0106177D0 (en)	2001-03-13	2001-05-02	Hoffmann La Roche	Piperazine derivatives
WO2002074746A1 (en)	2001-03-16	2002-09-26	Yamanouchi Pharmaceutical Co., Ltd.	Benzazepine derivatives
US6825198B2 (en)	2001-06-21	2004-11-30	Pfizer Inc	5-HT receptor ligands and uses thereof
EP1404679A2 (de)	2001-07-05	2004-04-07	PHARMACIA & UPJOHN COMPANY	(hetero)aryl substituierte benzofuranen als 5-ht liganden
MXPA04001202A (es)	2001-08-06	2005-02-17	Pharmacia & Upjhon Company	Ligandos tetraciclicos terapeuticamente utiles.
CA2453537A1 (en)	2001-08-08	2003-02-20	Pharmacia & Upjohn Company	Therapeutic 1h-pyrido¬4,3-b\|indoles
BR0212676A (pt)	2001-09-21	2006-05-23	Upjohn Co	compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
WO2003033497A1 (en) *	2001-10-18	2003-04-24	Pharmacia & Upjohn Company	Tetracyclic azaindoles and -indolines having serotonin 5-ht2c activity
JP2005516964A (ja)	2001-12-28	2005-06-09	バイエル・フアーマシユーチカルズ・コーポレーシヨン	５−ｈｔ２ｃレセプターと関連する疾患における使用のための１ｈ−ピラゾリル誘導体化合物
AU2002367323A1 (en)	2001-12-28	2003-07-24	Bayer Pharmaceuticals Corporation	Benzothieno (3,2-
AU2002360819A1 (en)	2001-12-28	2003-07-24	Bayer Corporation	Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
EP1465872A1 (de)	2001-12-28	2004-10-13	Bayer Pharmaceuticals Corporation	4-sulfid/sulfoxid/sulfonyl-1h-pyrazolderivate zur behandlung von erkrankungen, die mit 5-ht2c rezeptoren verbunden sind
JP4460450B2 (ja)	2002-06-19	2010-05-12	ビオヴィトルム・アクチボラゲット（プブリクト）	新規化合物、その使用および製造法

2004
- 2004-04-16 CL CL200400826A patent/CL2004000826A1/es unknown
- 2004-04-21 KR KR1020107019252A patent/KR20100103726A/ko not_active Ceased
- 2004-04-21 BR BRPI0409730-0A patent/BRPI0409730A/pt not_active IP Right Cessation
- 2004-04-21 EP EP04728610A patent/EP1620081A2/de not_active Withdrawn
- 2004-04-21 MX MXPA05011410A patent/MXPA05011410A/es unknown
- 2004-04-21 CA CA002670067A patent/CA2670067A1/en not_active Abandoned
- 2004-04-21 KR KR1020077022222A patent/KR20070108921A/ko not_active Ceased
- 2004-04-21 CA CA2523379A patent/CA2523379C/en not_active Expired - Fee Related
- 2004-04-21 CN CN2004800111992A patent/CN1780612B/zh not_active Expired - Fee Related
- 2004-04-21 JP JP2006506590A patent/JP2006524679A/ja active Pending
- 2004-04-21 EP EP10177541A patent/EP2277513A3/de not_active Withdrawn
- 2004-04-21 AU AU2004233745A patent/AU2004233745B2/en not_active Ceased
- 2004-04-21 KR KR1020057020223A patent/KR20060006063A/ko not_active Ceased
- 2004-04-21 WO PCT/IB2004/001437 patent/WO2004096196A2/en not_active Ceased
- 2004-04-23 TW TW093111427A patent/TW200426142A/zh unknown
- 2004-04-23 MY MYPI20041485A patent/MY142857A/en unknown
2005
- 2005-09-06 ZA ZA200507158A patent/ZA200507158B/en unknown
2010
- 2010-07-20 AU AU2010203093A patent/AU2010203093A1/en not_active Abandoned
- 2010-11-08 JP JP2010249395A patent/JP2011064695A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2004233745B2 (en)	2010-03-25
CL2004000826A1 (es)	2005-03-04
WO2004096196A2 (en)	2004-11-11
AU2010203093A1 (en)	2010-08-12
WO2004096196A3 (en)	2005-03-10
MY142857A (en)	2011-01-14
CA2523379C (en)	2010-06-22
BRPI0409730A (pt)	2006-05-09
KR20060006063A (ko)	2006-01-18
MXPA05011410A (es)	2005-12-12
KR20100103726A (ko)	2010-09-27
CN1780612B (zh)	2010-12-01
CN1780612A (zh)	2006-05-31
JP2006524679A (ja)	2006-11-02
JP2011064695A (ja)	2011-03-31
EP1620081A2 (de)	2006-02-01
CA2523379A1 (en)	2004-11-11
CA2670067A1 (en)	2004-11-11
KR20070108921A (ko)	2007-11-13
TW200426142A (en)	2004-12-01
EP2277513A2 (de)	2011-01-26
EP2277513A3 (de)	2011-09-07
AU2004233745A1 (en)	2004-11-11

Publication	Publication Date	Title
US20110152272A1 (en)	2011-06-23	Treatment Of Incontinence
AU2010203093A1 (en)	2010-08-12	Treatment of incontinence with 5-HT2C agonists
US6821975B1 (en)	2004-11-23	Beta-carboline drug products
AU773666B2 (en)	2004-06-03	Beta-carboline drug products
US20090162286A1 (en)	2009-06-25	Phosphodiesterase 10 Inhibition as Treatment for Obesity-Related and Metabolic Syndrome-Related Conditions
US20040235856A1 (en)	2004-11-25	Treatment of incontinence
RU2746601C2 (ru)	2021-04-16	Орвепитант для лечения хронического кашля
US9907795B2 (en)	2018-03-06	Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
Mennini et al.	1987	Mechanism of action of anxiolytic drugs
CA2609783A1 (en)	2006-12-07	Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US20050020646A1 (en)	2005-01-27	Treatment of BPH
CN101827597B (zh)	2013-03-13	睡眠障碍的治疗
JP2008546777A (ja)	2008-12-25	癌の治療のための４−アニリノ−３−キノリンカルボニトリル
WO2003032926A2 (en)	2003-04-24	Compositions and methods for reversal of drug resistance
HK1145282B (en)	2013-07-19	Treatment of sleep disorders